Challenges and opportunities for developing muscarinic receptor subtype-based therapeutic agents

Abstract

Drug Development ResearchVolume 40, Issue 2 p. 101-103 IntroductionFree Access Challenges and opportunities for developing muscarinic receptor subtype-based therapeutic agents James C. Blosser, Corresponding Author James C. Blosser Astra Arcus U.S.A., Rochester, New YorkAstra Arcus U.S.A., Rochester, New YorkSearch for more papers by this authorJohn E. Macor, John E. Macor Astra Arcus U.S.A., Rochester, New YorkSearch for more papers by this authorWilliam S. Messer Jr., William S. Messer Jr. Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OhioSearch for more papers by this author James C. Blosser, Corresponding Author James C. Blosser Astra Arcus U.S.A., Rochester, New YorkAstra Arcus U.S.A., Rochester, New YorkSearch for more papers by this authorJohn E. Macor, John E. Macor Astra Arcus U.S.A., Rochester, New YorkSearch for more papers by this authorWilliam S. Messer Jr., William S. Messer Jr. Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OhioSearch for more papers by this author First published: 06 December 1998 https://doi.org/10.1002/(SICI)1098-2299(199702)40:2<101::AID-DDR1>3.0.CO;2-PCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References Allard WJ, Sigal IS, Dixon RA (1987): Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor. Nucleic Acids Res 15: 10604. Bluml KE, Mutschler, Wess J (1994a): Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic receptors. J Biol Chem 269: 18870– 18876. Bluml KE, Mutschler, Wess J (1994b): Insertion mutagenesis as a tool to predict the secondary structure of a muscarinic receptor domain determining specificity of G-protein coupling. Proc Nat Acad Sci USA: 7980– 7984. Bonner TI, Buckley NJ, Young AC, Brann MR (1987): Identification of a family of muscarinic acetylcholine receptor genes. Science 237: 527– 532. Bonner TI, Young AC, Brann MR, Buckley NJ (1988): Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1: 403– 410. Dale HH (1914): The action of certain esters and ethers of choline, and their relation to muscarine. J Exp Ther 6: 147– 190. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC (1989): Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: Conserved aspartic acids play important roles in receptor functions. Mol Pharmacol 36: 840– 847. Hammer R, Giachetti A (1982): Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci 31: 2991– 2998. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980): Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283: 90– 92. Hibert MF, Trump-Kallmeyer S, Bruinvels A, Hoflack J (1991): Threedimensional models of neurotransmitter G-binding protein coupled receptors. Mol Pharmacol 40: 8– 15. Lai J, Mei L, Roeske WR, Chung FZ, Yamamura HI, Venter JC (1988): The cloned murine M1 muscarinic receptor is associated with the hydrolysis of phosphatidylinositols in transfected murine B82 cells. Life Sci 42: 2489– 2502. Loewi O (1921): über humorale übertragbarkeit der herznervenwirkung. Pflüegers Arch Gesamte Physiol 189: 239– 242. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991): Identification and localization of muscarinic acetylcholine receptor proteins with subtype-specific antibodies. J Neurosci 11: 3218– 3226. Nordvall G, Hacksell U (1993): Binding-site modeling of the muscarinic m1 receptor: A combination of homology-based and indirect approaches. J Med Chem 36: 967– 976. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. (1987): Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 6: 3023– 3029. Wall SJ, Yasuda RP, Li M, Wolfe BB (1991): Development of an antiserum against m3 muscarinic receptors: Distribution of m3-receptors in rat tissues and clonal cell lines. Mol Pharmacol 40: 783– 789. Ward JS, Merritt L, Klimlowski VJ, Lamb ML, Mitch CH, Bymaster FP, Sawyer B, Shannon HE, Olesen PH, Honore T (1992): Novel functional M1 selective muscarinic agonists. II. Synthesis and structure-activity relationships of 3-(pyrazinyl)-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore. J Med Chem 35: 4011– 4019. Wess J, Bonner TI, Dorje G, Brann MR (1990): Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Mol Pharmacol 38: 517– 523. Wess J, Maggio R, Palmer JR, Vogel Z (1992): Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation: A study with m3 muscarinic receptor point mutants. J Biol Chem 267: 19313– 19319. Citing Literature Volume40, Issue2February 1997Pages 101-103 ReferencesRelatedInformation